Know Cancer

forgot password

Epigenetic Testing for Breast Cancer Risk Stratification

30 Years
79 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

Epigenetic Testing for Breast Cancer Risk Stratification

Inclusion Criteria:

- Women between the ages of 30 and 79.

- Untreated stage 1 - 3 invasive breast cancer or a woman never diagnosed with breast

- BI-RADS 1, 2, or 3 breast imaging within 12 months for women >40 years of age
recruited into the control group.

Exclusion Criteria:

- <30 or >80 years of age

- Unable to provide informed consent

- Presence of an undefined palpable or mammographic breast lesion suspicious for
malignancy (BIRADS 4 or 5)

- Breast implants

- Bilateral prophylactic mastectomy

- Any prior breasts irradiation

- Any systemic chemotherapy in the past

- Performance status that restricted normal activity for a significant portion of the

- Use of luteinizing-hormone-releasing-hormone (LHRH) analogs, prolactin inhibitors,
antiandrogens, or systemic glucocorticoids within three months

- Ever use of tamoxifen, raloxifene, or other SERMs

- Ever use of aromatase inhibitors

- Pregnancy or lactation within six months

- Bleeding diathesis of any kind

1. Inherited coagulation disorder

2. Current coumadin use

3. Use of drugs that inhibit platelet aggregation within 10 days

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

David Euhus, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UT Southwetsren Medical Center


United States: Army Medical Research and Materiel Command (USAMRMC)

Study ID:

STU 092011-047



Start Date:

January 2012

Completion Date:

January 2015

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms



Ut Southwestern Medical Center Dallas, Texas  75390